Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 6/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414036 | 0.88 | ABCG2 (0.50) | TNFRSF1AAPPPTPN1MAOB | |
| SCHEMBL18526959 | 0.83 | PDE4A (0.60) | TNFRSF1AAPPPDE4APDE4BPDE4C | |
| SCHEMBL8064391 | 0.82 | PTPN1 (0.56) | TNFRSF1AAPPPTPN1PDE4APDE4B | |
| SCHEMBL17237769 | 0.82 | MAOB (0.67) | TNFRSF1AAPPPTPN1MAOB | |
| SCHEMBL8052936 | 0.81 | PTPN1 (0.57) | TNFRSF1AAPPPTPN1MAOB | |
| SCHEMBL4883621 | 0.79 | ABCG2 (0.65) | APPPTPN1MAOB | |
| SCHEMBL5318918 | 0.79 | ABCG2 (0.65) | APPPTPN1MAOB | |
| SCHEMBL27630436 | 0.76 | ABCG2 (0.50) | PTPN1MAOB | |
| SCHEMBL24983864 | 0.75 | PDE4A (0.63) | TNFRSF1AAPPPDE4APDE4BPDE4C | |
| SCHEMBL29179321 | 0.75 | PDE4A (0.63) | TNFRSF1AAPPPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10058582-B2 | Therapeutic molecules and deviates for CRC | ANTARTINA LLC (US) | 2018-08-28 | — | — | US | disclosed |
| US-20170049839-A1 | Therapeutic molecules & deviates for CRC | NEOCAGE SL (AD) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10058582-B2 | Therapeutic molecules and deviates for CRC | DLD, APC, SEPTIN7 | TNFRSF1A 4307/4885APP 3500/4885PTPN1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.